Objective Our aim was to correlate the in vitro and in vivo CYP1A2 inhibition potential of
tolfenamic acid, an NSAID highly (99.7%) bound to plasma proteins, to study the …

Aims The aim of the study was to clarify whether the pharmacokinetic interaction between
theophylline and mexiletine is mediated by inhibition of CYP1A2 and to assess the possible …

Objective Our objective was to study the effect of fluvoxamine on the pharmacokinetics and
pharmacodynamics of tizanidine, a centrally acting skeletal muscle relaxant. Methods In a …

Objective Our objective was to examine the interaction between fluvoxamine and
tolbutamide to confirm that fluvoxamine inhibits CYP2C9. Methods The study was carried out …

Purpose. To assess the degree to which the maximum unboundconcentration of inhibitor at
the inlet to the liver (I inlet, u, max), used in theprediction of drug-drug interactions …

Objectives Nateglinide is metabolized by CYP2C9 and CYP3A4, therefore drug–drug
interactions through cytochrome P450 (CYP) inhibition may occur. In this study, we …

Objective Several reports indicate that fluvoxamine decreases the clearance of cytochrome
P4501A2 (CYP1A2) substrates. This study compared in vitro and in vivo inhibition potencies …

Aims To identify the cytochrome P450 (CYP) enzyme (s) that catalyze the metabolism of
tizanidine in vitro. Methods The effect of CYP isoform inhibitors on the elimination of …

Abstract Tenapanor (RDX5791, AZD1722) is an inhibitor of sodium/hydrogen exchanger
isoform 3 in development for the treatment of constipation‐predominant irritable bowel …

In this study, we report the effect of dimethyl sulfoxide (DMSO), acetonitrile, and methanol on
the CYP1A2-mediated metabolism of phenacetin in human liver microsomes. Phenacetin O …